SAN MATEO, Calif., Nov. 8, 2011 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (Nasdaq:NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, announced it will hold a conference call today, Tuesday, November 8, 2011 at 8:30 a.m. ET (5:30 a.m. PT) to report results for its Phase 2 clinical study of NGX-1998, a topical liquid formulation of high-concentration capsaicin, in patients with postherpetic neuralgia (PHN).
The conference call will be hosted by Anthony DiTonno, President and Chief Executive Officer, Dr. Stephen Peroutka, recently appointed Executive Vice President and Chief Medical Officer, and Dr. Mark Wallace, a clinical investigator for the Phase 2 study.
To participate, please dial 1-877-407-0784 or 1-201-689-8560 (International). Slides to be presented live on the call will be available beginning at 7:30 a.m. ET. They can be accessed here, or on the Events page under the Investor Relations section of the Company website, www.neurogesx.com.
A replay of the conference call will be available beginning November 8, 2010 at 11:30 a.m. ET (8:30 a.m. PT) and ending on November 15, 2011, by dialing 1-877-870-5176 (USA) or 1-858-384-5517 (International), PIN Number: 382935.
About NeurogesX, Inc.
NeurogesX, Inc. (Nasdaq:NGSX) is a San Francisco Bay Area-based biopharmaceutical company focused on developing and commercializing novel pain management therapies. NeurogesX was founded on the concept that use of prescription-strength capsaicin could help manage the pain associated with neuropathic pain conditions. Since its inception, NeurogesX has leveraged its passion to help people with pain to efficiently develop this concept, resulting in the commercial launch of Qutenza (capsaicin) 8% patch in 2010. The Company continues to apply its knowledge and expertise in the development of other novel treatments for pain.
The Company's lead product, Qutenza, is a localized dermal delivery system containing prescription strength capsaicin that is currently approved in the United States and the European Union. Qutenza is now available in the United States for the management of neuropathic pain associated with postherpetic neuralgia (PHN). In Europe, Qutenza is being marketed by Astellas Pharma Europe Ltd. (Astellas), the European subsidiary of Tokyo-based Astellas Pharma Inc., for the treatment of peripheral neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain.
The Company has submitted a supplemental new drug application (sNDA) to expand the U.S. label for Qutenza for the management of pain due to HIV-associated peripheral neuropathy (HIV-PN) also known as HIV-associated neuropathy (HIV-AN) and HIV-distal sensory polyneuropathy (HIV-DSP).
The Company's most advanced product candidate, NGX-1998, is a topically applied liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions such as PHN. NGX-1998 has completed three Phase 1 studies and patient enrollment and dosing has been completed in a Phase 2 clinical trial in PHN patients.
The Company's early-stage pipeline includes pre-clinical compounds which include a number of prodrugs of acetaminophen. The Company has evaluated certain of these compounds in vitro and in vivo.
Forward Looking Statement
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the Act). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include but are not limited to statements regarding: the potential for a Phase 2 meeting with the FDA, including the timing of such meeting; the potential safety and efficacy of NGX-1998[, including as compared to Qutenza]; plans with respect to a potential Phase 3 program for NGX-1998; plans to seek a partnership for NGX-1998 in the United States and other markets; and the timing of Dr. Peroutka assuming the position of Executive Vice President and Chief Medical Officer. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: difficulties or delays in further clinical development of NGX-1998; NGX-1998, or NeurogesX approved product Qutenza, may have unexpected adverse side effects; unexpected or increased expenses in the continued development of NGX-1998 or Qutenza; market acceptance of NeurogesX's existing product Qutenza; and difficulties in maintaining adequate funding or other resources for NeurogesX operations and development of NGX-1998. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.